Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives

International Consortium for Therapeutic Drug Monitoring

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory bowel disease (IBD). However, challenges remain and are hindering the widespread implementation of TDM in clinical practice. These barriers include identification of the optimal drug concentration to target, the lag time between sampling and results, and the proper interpretation of anti-drug antibody titres among different assays. Solutions to overcome these barriers include the harmonisation of TDM assays and the use of point-of-care testing. Other unmet needs include well designed prospective studies and randomised controlled trials focusing on proactive TDM, particularly during induction therapy. Future studies should also investigate the utility of TDM for biologics other than anti-TNF therapies in both IBD and other immune-mediated inflammatory diseases such as rheumatoid arthritis and psoriasis, and the use of pharmacokinetic modelling dashboards and pharmacogenetics towards individual personalised medicine.

Original languageEnglish
Pages (from-to)171-185
Number of pages15
JournalThe Lancet Gastroenterology and Hepatology
Issue number2
StatePublished - Feb 2022


Dive into the research topics of 'Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives'. Together they form a unique fingerprint.

Cite this